UY39083A - Formulaciones de anticuerpos anti-tslp humanos y métodos de tratamiento de una enfermedad inflamatoria - Google Patents
Formulaciones de anticuerpos anti-tslp humanos y métodos de tratamiento de una enfermedad inflamatoriaInfo
- Publication number
- UY39083A UY39083A UY0001039083A UY39083A UY39083A UY 39083 A UY39083 A UY 39083A UY 0001039083 A UY0001039083 A UY 0001039083A UY 39083 A UY39083 A UY 39083A UY 39083 A UY39083 A UY 39083A
- Authority
- UY
- Uruguay
- Prior art keywords
- tslp antibody
- inflammatory disease
- treatment methods
- human anti
- antibody formulations
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Organic Chemistry (AREA)
- Dermatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
En la presente se proporcionan composiciones acuosas que comprenden (a) un anticuerpo anti-TSLP a una concentración mayor que aproximadamente 140 mg/ml, (b) un tensioactivo y (c) al menos un aminoácido básico o una sal del mismo. También se proporcionan composiciones acuosas que comprenden composiciones acuosas que comprenden (a) un anticuerpo anti-TSLP a una concentración mayor que aproximadamente 140 mg/ml, (b) un tensioactivo y (c) al menos una sal de calcio o sal de magnesio. También se proporcionan artículos de fabricación relacionados, jeringas precargadas y viales que comprenden las composiciones de la presente divulgación.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062976007P | 2020-02-13 | 2020-02-13 | |
| US202163148105P | 2021-02-10 | 2021-02-10 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UY39083A true UY39083A (es) | 2021-08-31 |
Family
ID=74858823
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UY0001039083A UY39083A (es) | 2020-02-13 | 2021-02-12 | Formulaciones de anticuerpos anti-tslp humanos y métodos de tratamiento de una enfermedad inflamatoria |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20230078678A1 (es) |
| EP (1) | EP4103235A1 (es) |
| JP (1) | JP2023513312A (es) |
| KR (1) | KR20220140772A (es) |
| CN (1) | CN115279404A (es) |
| AU (1) | AU2021219839A1 (es) |
| BR (1) | BR112022016010A2 (es) |
| CA (1) | CA3166964A1 (es) |
| CL (1) | CL2022002193A1 (es) |
| CO (1) | CO2022012868A2 (es) |
| CR (1) | CR20220457A (es) |
| IL (1) | IL295042A (es) |
| JO (1) | JOP20220183A1 (es) |
| MX (1) | MX2022010012A (es) |
| PE (1) | PE20230112A1 (es) |
| UY (1) | UY39083A (es) |
| WO (1) | WO2021163504A1 (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12110324B2 (en) | 2022-07-22 | 2024-10-08 | Flagship Pioneering Innovations Vi, Llc | Antigen binding molecules targeting thymic stromal lymphopoietin (TSLP) |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| ATE158021T1 (de) | 1990-08-29 | 1997-09-15 | Genpharm Int | Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper |
| US7982016B2 (en) | 2007-09-10 | 2011-07-19 | Amgen Inc. | Antigen binding proteins capable of binding thymic stromal lymphopoietin |
| US8359965B2 (en) | 2007-09-17 | 2013-01-29 | Oxford J Craig | Apparatus and method for broad spectrum radiation attenuation |
| TW201018482A (en) | 2008-08-08 | 2010-05-16 | Glaxo Wellcome Mfg Pte Ltd | Novel treatment |
| AU2010315304B2 (en) | 2009-11-04 | 2014-03-27 | Merck Sharp & Dohme Llc | Engineered anti-TSLP antibody |
| WO2012007495A1 (en) | 2010-07-15 | 2012-01-19 | F. Hoffmann-La Roche Ag | Antibodies specifically binding to human tslpr and methods of use |
| AT510032B1 (de) | 2010-11-30 | 2012-01-15 | Steiner Erwin Ing | Montageeinrichtung für fassadenelemente |
| US9100245B1 (en) | 2012-02-08 | 2015-08-04 | Amazon Technologies, Inc. | Identifying protected media files |
| WO2014031718A1 (en) * | 2012-08-23 | 2014-02-27 | Merck Sharp & Dohme Corp. | Stable formulations of antibodies to tslp |
| US9306926B2 (en) | 2013-03-15 | 2016-04-05 | Brian A. Truong | User authentication using unique hidden identifiers |
| EP3268032A1 (en) | 2015-03-11 | 2018-01-17 | GlaxoSmithKline Intellectual Property Development Limited | Tslp binding proteins |
| TN2018000076A1 (en) | 2015-09-09 | 2019-07-08 | Novartis Ag | Thymic stromal lymphopoietin (tslp)-binding molecules and methods of using the molecules |
| CA3008779A1 (en) * | 2015-12-18 | 2017-06-22 | Astellas Pharma Inc. | Pharmaceutical composition comprising anti-human tslp receptor antibody |
| JOP20190243A1 (ar) * | 2017-04-12 | 2019-10-13 | Medimmune Llc | علاج الربو بجسم مضاد لـ tslp |
| CN110709121B (zh) | 2017-06-08 | 2022-06-24 | 安进公司 | 扭矩驱动式药物递送装置 |
| AU2018364933B2 (en) | 2017-11-10 | 2024-01-25 | Amgen Inc. | Plungers for drug delivery devices |
| ES2965064T3 (es) | 2018-03-13 | 2024-04-10 | Amgen Inc | Métodos para la preparación de polipéptidos resistentes a tripsina para análisis espectrométrico de masas |
| KR20210076935A (ko) | 2018-10-15 | 2021-06-24 | 암젠 인크 | 댐핑 메커니즘을 갖는 약물 전달 장치 |
| SG11202101824VA (en) | 2018-10-15 | 2021-03-30 | Amgen Inc | Platform assembly process for drug delivery device |
-
2021
- 2021-02-12 IL IL295042A patent/IL295042A/en unknown
- 2021-02-12 CA CA3166964A patent/CA3166964A1/en active Pending
- 2021-02-12 AU AU2021219839A patent/AU2021219839A1/en active Pending
- 2021-02-12 PE PE2022001741A patent/PE20230112A1/es unknown
- 2021-02-12 UY UY0001039083A patent/UY39083A/es unknown
- 2021-02-12 US US17/760,427 patent/US20230078678A1/en active Pending
- 2021-02-12 EP EP21710162.5A patent/EP4103235A1/en active Pending
- 2021-02-12 CN CN202180017163.9A patent/CN115279404A/zh active Pending
- 2021-02-12 WO PCT/US2021/017880 patent/WO2021163504A1/en active Application Filing
- 2021-02-12 BR BR112022016010A patent/BR112022016010A2/pt unknown
- 2021-02-12 JO JOP/2022/0183A patent/JOP20220183A1/ar unknown
- 2021-02-12 MX MX2022010012A patent/MX2022010012A/es unknown
- 2021-02-12 KR KR1020227030979A patent/KR20220140772A/ko unknown
- 2021-02-12 CR CR20220457A patent/CR20220457A/es unknown
- 2021-02-12 JP JP2022548653A patent/JP2023513312A/ja active Pending
-
2022
- 2022-08-12 CL CL2022002193A patent/CL2022002193A1/es unknown
- 2022-09-09 CO CONC2022/0012868A patent/CO2022012868A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20230078678A1 (en) | 2023-03-16 |
| MX2022010012A (es) | 2022-09-07 |
| CO2022012868A2 (es) | 2022-12-09 |
| JOP20220183A1 (ar) | 2023-01-30 |
| CN115279404A (zh) | 2022-11-01 |
| KR20220140772A (ko) | 2022-10-18 |
| IL295042A (en) | 2022-09-01 |
| JP2023513312A (ja) | 2023-03-30 |
| WO2021163504A1 (en) | 2021-08-19 |
| CL2022002193A1 (es) | 2023-03-24 |
| CR20220457A (es) | 2023-01-09 |
| BR112022016010A2 (pt) | 2022-12-20 |
| CA3166964A1 (en) | 2021-08-19 |
| EP4103235A1 (en) | 2022-12-21 |
| PE20230112A1 (es) | 2023-01-27 |
| AU2021219839A1 (en) | 2022-08-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2021008055A2 (es) | Heterociclos funcionalizados como agentes antivirales | |
| Kryshchyshyn et al. | Trends in research of antitrypanosomal agents among synthetic heterocycles | |
| CY1118059T1 (el) | Συνθεσεις αντιλοιμωδων βασει λιπιδιων για αγωγη πνευμονικων λοιμωξεων | |
| BR0316397A (pt) | Tiouréias aril substituìdas e compostos relacionados como inibidores de replicação viral | |
| BRPI0506705A (pt) | composto de tiouréias azabenzofuran-substituìdas, composições farmacêuticas e seus usos | |
| ATE538774T1 (de) | Pharmazeutische formulierungen und verfahren zur behandlung von atemwegsinfektionen | |
| CY1113948T1 (el) | Θεραπευτικα δραστικα αλφα-msh αναλογα | |
| ES2063011T3 (es) | Agentes antibacteriales de quinolonas y naftiridinas que contienen un alfa-aminoacido en la cadena lateral del 7-sustituyente. | |
| UY38383A (es) | Heterociclos funcionalizados como agentes antivirales | |
| AR048439A1 (es) | Composiciones farmaceuticas y metodos para tratar la infeccion por vih | |
| AR117707A1 (es) | Formulación de solución de proteínas que contiene una alta concentración de un anticuerpo anti-vegf | |
| UY39083A (es) | Formulaciones de anticuerpos anti-tslp humanos y métodos de tratamiento de una enfermedad inflamatoria | |
| CY1110644T1 (el) | 5,6,7-τριυδροξυεπτανοϊκο οξυ και τα αναλογα για την θεραπεια οφθαλμικων ασθενειων που σχετιζονται με υπερεκφυτικες και αγγειογενεις αντιδρασεις | |
| CO2019004004A2 (es) | Composición farmacéutica y método para el tratamiento de la enfermedad del hígado graso no alcohólico | |
| AR039895A1 (es) | Composicion que comprende una vitamina, una sal de metal y una insulina o una hormona del crecimiento y uso de dichos componentes para prepararla | |
| CY1119308T1 (el) | Συνδυασμοι με ενα πεπτιδιο κυκλοποιημενου σκελετου | |
| AR121329A1 (es) | Formulaciones de anticuerpos anti-tslp humanos y métodos de tratamiento de una enfermedad inflamatoria | |
| AR125470A1 (es) | Composición farmacéutica de pembrolizumab y su uso | |
| MX2023000004A (es) | Formulaciones para promover la hidratacion y metodos de uso de las mismas. | |
| EA201791906A1 (ru) | Вакцина на основе гибридного белка и днк для профилактики и лечения туберкулеза (варианты) | |
| AR119805A1 (es) | Composición farmacéutica acuosa de anticuerpo anti-pd1 prolgolimab y su uso | |
| CO2020001742A2 (es) | Composiciones sólidas orales de betahistina de liberación prolongada no pulsátil | |
| HN2006023741A (es) | " formulaciones de liberacion prolongada de principios activos de zolpidem hemitartrato" | |
| WO2020139163A3 (ru) | Комбинация противовирусных средств | |
| Siemieniuk et al. | Preexposure prophylaxis for HIV infection |